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Abstract: Brain primary tumors are among the most diverse and complex human cancers, and are 12 
classified on the basis of both the cell-type and/or the brain structure from which they arise, as well 13 
as of the grade of malignancy, the most malignant being glioblastoma multiforme (GBM, grade IV). 14 
Glioma cells are able to migrate throughout the brain and to stimulate angiogenesis, by inducing 15 
brain capillary endothelial cell proliferation. This causes in turn loss of tight junctions and fragility 16 
of the blood-brain barrier, which becomes leaky. As a consequence, the most serious clinical 17 
complication of glioblastoma is the vasogenic brain edema. Both glioma cell migration and edema 18 
have been correlated with modification of the expression/localization of different isoforms of 19 
aquaporins (AQPs), a family of water channels, some of which are also involved in the transport of 20 
other small molecules, such as glycerol and urea. In this review we discuss relationships among 21 
expression/localization of AQPs and brain tumors/edema, also focusing on the possible role of 22 
these molecules as both diagnostic biomarkers of cancer progression, and therapeutic targets. 23 
Finally, we will discuss the possibility that AQPs, together with other cancer promoting factors, can 24 
be exchanged among brain cells via extracellular vesicles (EVs). 25 
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 28 
1. Introduction 29 
Central Nervous System (CNS) tumors are among the most complex human cancers and constitute a 30 
group of anatomically similar, but still diverse tumor species with different morphology, aetiology, 31 
site of origin, molecular biology, and clinical progression [1]. 32 
Most primary cancers of the adult brain originate from glial cells or glial cell precursors and are 33 
called as a whole gliomas, further subdivided into astrocytomas, oligodendrogliomas, 34 
ependymomas, and glioastrocytomas [2,3]. Concerning the grade of malignancy, 35 
oligodendrocytomas and mixed gliomas are classified as II and III grade, while astrocytomas are 36 
subdivided into low-grade- (LGA: pilocytic, grade I, and diffuse, grade II) and high-grade- (HGA: 37 
anaplastic, grade III, and glioblastoma multiforme, GBM, grade IV) astrocytomas [4]. HGA are 38 
mostly treated by surgery, followed by radiation and chemiotherapy [4]. However, because of the 39 
high infiltrating capacity of glioma cells, and in spite of great advancements of both 40 
radio-/chemo-therapeutic and surgical protocols, therapy of HGA still remains almost ineffective, 41 
with less than 10% of patients surviving for more than three years [5-7].  42 
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A further problem concerns early identification of a brain tumor: for a variable period of time after 43 
the onset of cancer, indeed, patients may suffer from only unspecific symptoms, such as seizures and 44 
headache [4]. 45 
A critical aspect of brain tumors is their contrasting relationship with the blood-brain barrier (BBB), 46 
both in tumor diagnosis and therapy: if, indeed, on one hand, BBB hampers identification and 47 
treatment of cancer, by forming a barrier which often opposes to drug access into the brain [8,9], on 48 
the other hand, paradoxically, BBB becomes leaky because of cancer, thus causing vasogenic brain 49 
edema, the most frequent and serious clinical complication of GBM [10]. Moreover, brain cancer cells 50 
are able to actively induce neuronal- [11] as well as glial- [12] cell death, and neurodegeneration, 51 
associated with cytotoxic edema [10,13]. These latter events probably involve, at least in part, the 52 
ability of cancer cells to produce and release into their environment extracellular vesicles (EVs), 53 
which contain a collection of different factors, able to promote cancer progression by suppressing 54 
immune response, while stimulating cancer growth and invasion, angiogenesis, and metastatic 55 
spreading [14]. 56 
Both cytotoxic and vasogenic edemas seem to depend on altered expression and/or localization of 57 
water channels, belonging to the aquaporin family (AQPs). Here we summarize the possible roles 58 
played by aquaporins in physiological brain functions as well as in brain tumors, in relationship 59 
with both kinds of edema. 60 
2. Brain circulation and aquaporins 61 
The cell membrane is a highly integrated system, dynamically responsive and reactive to 62 
environmental conditions, and linked to many other cell structures, such as the cytoskeleton, inside 63 
the cell, and the extracellular matrix, outside [15]. Importantly, membrane molecules can form 64 
domains of different sizes (from nano- to micro-sized), in reversible, non-uniform, non-random 65 
manner [16], which, by interacting with other cell structures, cause partitioning of proteins and 66 
lipids, and generation of membrane corrals characterized by high densities of specific molecular 67 
complexes [15]. A fundamental property of cell membranes is  their capacity to allow rapid and 68 
highly regulated water transport. Fluid transport in tissues actually follows two routes: i) 69 
transcellular, between apical and basal cell membranes, driven by osmotic stimuli, and ii) paracellular, 70 
in the inter-cellular spaces, across cell-to-cell junctions [17,18].  71 
2.1. Brain circulation 72 
The brain parenchyma has been traditionally considered a lymphatic vasculature-lacking organ, 73 
from which the necessity to envisage alternative pathways for clearance of solutes and water from 74 
the interstitial fluid (ISF) of the extracellular space (ECS), and from the cerebrospinal fluid (CSF), 75 
which is produced by active secretion from the choroid plexus,  and flows in the ventricles and the 76 
subarachnoid space (SAS). In the brain we can actually recognize four distinct water compartments: 77 
intracellular fluid (ICF), ISF, CSF and blood. ICF composition shows significant differences when 78 
different cell types (i.e. neurons and glial cells) are compared; for example, neurons keep chloride 79 
concentration lower than glial cells, thanks to the presence in their membrane of potassium chloride 80 
cotransporter (KCC) 2 [19]. Moreover, astrocytes have a higher water permeability than neurons 81 
because of high concentration of the aquaporin protein AQP4 (see below) [20]. Interestingly, ISF and 82 
CSF have similar composition, thus suggesting a CSF-ISF dynamic exchange of solutes and water. 83 
Since about thirty years ago, many observations suggested, indeed, that CSF can flow throughout 84 
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the brain along paravascular spaces running along cortical arteries [21,22]. Based on these 85 
observations as well as on the functional similarity with the peripheral lymphatic system, and on the 86 
important role played by glial cells in cerebral water flowing, other researchers suggested  the 87 
existence, throughout the brain, of a water-exchanging network, driven by cerebral arterial 88 
pulsation, which was termed “glymphatic” system [20,23,24].  89 
It has been also reported that CSF is finally drained into extracranial lymphatic vessels and lymph 90 
nodes (LNs). Recently, in a transgenic mouse model with complete aplasia of the dural lymphatic 91 
vessels, Aspelund et al. [25] observed complete abrogation of transport from the subarachnoid space 92 
into LNs. Based on this observation, the Authors suggested that CSF flux into the LNs is mediated 93 
through a dural lymphatic network. Similar observations have been also reported by Louveau et al. 94 
[26], and have been vivaciously discussed also in the context of removal from the brain of waste 95 
 96 
Finally, as long as the vascular compartment is concerned, its almost complete independence from 97 
the other water compartments is well known and due to the blood-brain-barrier (BBB), a highly 98 
selective structure formed by brain capillary endothelial cells (BCECs) [28-35]. In most of our body, 99 
endothelial cells, that form the walls of  capillaries, have gaps, while  BCECs are tightly sealed 100 
together thanks to the tight junctions (TJs). Moreover, BCECs do not possess aquaporins (see below) 101 
[36]. 102 
TJs are formed by many different proteins, among which claudins [37,38] and occludin [39,40], and 103 
the quality of the BBB function indeed depends on correct synthesis, post-translational modification, 104 
and peripheral localization of these proteins. Importantly, formation and maturation of TJs depend 105 
in turn on the brain microenvironment and on glial cells and perycytes [41]. By using an in vitro 106 
model of BBB, we demonstrated that not only astrocytes but also neurons can affect BBB formation 107 
and maintenance [42-44]; these effects are probably due to secretion of angiogenic factors, such as 108 
VEGF and FGF-2, which are released, at least in part, through extracellular vesicles [45,46]. In the 109 
same co-culture system it was also found that BBB can be damaged by factors present in the serum of 110 
patients affected by multiple sclerosis, and that BBB breaking is accompanied by a decrease of the 111 
synthesis, and peripheral localization, of occluding [47].  112 
2.2. General properties of aquaporins (AQPs) 113 
Although partially due to passive co-transport with other molecules and ions [48], transcellular 114 
water flow is mostly mediated by specialized water channels called aquaporins (AQPs). Since their 115 
discover in erythrocytes [49] and renal tubules [50,51], at least 13 different isoforms of AQPs have 116 
been identified as channels widely expressed in various fluid-transporting epithelial and endothelial 117 
cells in mammals, and able to modulate the capacity of cells to control their volume, in response to a 118 
changing osmotic environment [18,52,53]. Different AQP isoforms have different tissue localization 119 
and specific functions: AQP0, AQP1, AQP2, AQP4, AQP5, and AQP8 are water channels, while 120 
AQP3, AQP7, AQP9, and AQP10, also called aquaglyceroporins, are also able to transport other 121 
polar molecules, such as glycerol and urea, and probably also some non-polar gases, such as CO2 122 
and O2 [36]. In addition, a third group of AQPs, with low homology to the already known ones, has 123 
been recently identified and termed superaquaporin family [54]. This latter group includes AQP11 124 
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and AQP12, two AQPs present in the cytoplasm and probably involved in the maintenance of 125 
organelle volume [55]. 126 
AQPs exist in cell membranes as tetramers; each monomer is a 28-30 kDa protein, which contains six 127 
trans- -helices, forming a barrel structure, and lining an independent channel; the 128 
narrowest part of this pore contains conserved Asn-Pro-Ala (NPA) motifs. Assembly of the four 129 
subunits also determines formation of a central space which has been suggested to be permeable for 130 
gases, in AQP1, AQP4 and AQP5 [56-59].  131 
Although AQPs generally form homo-tetramers, AQP4 can also form hetero-tetramers. Two 132 
different isoforms of AQP4 monomers, indeed, exist [60-62]: i) a longer AQP-M1 isoform, with 133 
translation initiation at met 1, and ii) a shorter AQP-M23 isoform, with translation initiation at met 134 
23. The two isoforms can form both homo- and hetero-tetramers with different localization and 135 
properties; of particular interest (see below) is the ability of the M23-containing tetramers to 136 
assemble into supramolecular complexes, known as orthogonal arrays of particles (OAPs) [36,63-65]. 137 
2.3 AQP expression and function in the nervous system 138 
The main AQPs present in the central nervous system are AQP1, AQP4 and AQP9 [18,66-68]. AQP1 139 
is expressed in the choroid plexus epithelium and seems to be involved in the formation of CSF [69], 140 
while AQP4 is present both in astrocytes [18,70] and neurons [71]. No AQP is present in the BCECs 141 
which constitute the anatomical basis of the BBB. However, AQP4 distribution in astrocytes is highly 142 
polarized to astrocytic endfeet which contact the blood vessels at the BBB, as well as at the CNS-CSF 143 
interface (glia limitans) [72]. At these sites, AQP4 is included in the already mentioned OAPs, the 144 
formation and polarity of which are established during development, in parallel with maturation of 145 
the BBB [63,73]. The density of AQP4/OAPs is particularly high (100–400/μm2) at the sites where the 146 
astrocyte membrane directly contacts the perivascular as well as the superficial basal lamina, at the 147 
surface of the brain, while, when the membrane turns back from the basal lamina, the density of 148 
OAPs dramatically decreases to about 10–20/μm2 [74-77]. This peculiar AQP4 localization in the 149 
surroundings of cerebral capillaries suggests a role for AQP4 in extracellular fluid clearance. OAP 150 
forrmation and localization in astrocytes depend on their interaction with both intracellular 151 
scaffolding pro -syntrophin [78], and extracellular  proteoglycans, such as agrin, an 152 
-dystroglycan, a component of the 153 
dystrophyn-dystroglycan complex, found at many sites in the CNS [75]. Interestingly, these 154 
complexes also contain the inwardly rectifying potassium channel Kir4.1, a protein involved in 155 
spatial buffering of K+ ions released, because of synaptic activity, into the extracellular space. K+ ions 156 
are taken up by astrocytes and water osmotically follows them through the AQP4 pores [41]. In 157 
general, polarized AQP4 expression characterizes the boundaries between the brain and various 158 
fluid compartments, thus suggesting its involvement in regulation of water flow in and out of the 159 
brain [36]. 160 
AQP9 is a member of the aquaglyceroporin family, probably involved not only in water flux across 161 
the plasma membrane, but also in permeation of monocarboxylates, such as lactate and 162 
-hydroxybutyrate, and other solutes, such as glycerol, purines, pyrimidines and urea [79]. AQP9 163 
expression has been evidenced in many sites, and different cytotypes, including astrocytes and 164 
catecholaminergic neurons [79-82]. 165 
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In addition to the main AQPs, at a lower concentration and with still unknown physiologic 166 
functions, other AQPs have been reported to be present in the CNS, based on RT-PCR [83], 167 
immunohistochemistry, and immunofluorescence [84].  168 
AQP8, an AQP widely expressed in the reproductive systems, in the epithelia of the digestive tract, 169 
in liver, and pancreas, has been, for example, also evidenced in various CNS areas, such as piriform 170 
cortex, choroid plexus, and hippocampus. Several studies showed that AQP8 channels are present in 171 
the inner mitochondrial membrane of various tissues, suggesting a role in the osmotic equilibrium of 172 
these intracellular organelles and perhaps in the maintenance of acid–base equilibrium [84].  173 
AQP3, and AQP5 seem to be also present, with a distribution patterns similar to AQP8 [84]. 174 
Finally, expression of the superaquaporin AQP11 in the CNS, and in particular in Purkinje cells of 175 
the cerebellum [85], in the epithelium of the choroid plexus and perhaps in BCECs [54] has been 176 
reported. Its function in these sites, however, remains to be clarified. 177 
3. Brain tumors and aquaporins 178 
3.1 Epidemiology of brain tumors 179 
Primary CNS cancers are among the top 10 causes of tumor-related deaths in the United States, 180 
accounting for approximately 1.4% of all cancers and 2.4% of all cancer-related deaths. [86]. In 181 
European countries, standardized incidence of primary brain tumors is comprised between 4.5 and 182 
11.2 cases/100,000 men, and between 1.6 and 8.5/100,000 women. [1]. Increases in the incidence of 183 
malignant brain tumors  have been attributed to several factors: improved diagnostic procedures, 184 
such as computed tomography and magnetic resonance imaging (MRI); a greater availability of 185 
neurosurgeons and changing patterns of access to medical care. Although analytic epidemiologic 186 
studies have suggested involvement of environmental factors, no specific risk factor, accounting for 187 
large percentages of brain tumors, has been identified up to now [86]. 188 
As mentioned, most primary tumors in the adult are gliomas (42% of all primary CNS tumors and 189 
77% of all malignant ones). Among gliomas, diverse histological lineages can be distinguished, 190 
including astrocytoma, oligodendroglioma, and mixed oligoastrocytoma. For all these cytotypes, 191 
both low-grade and high-grade variants are known, and all have the potential to evolve into highly 192 
malignant tumors, resistant to treatment, and named glioblastoma multiforme (GBM  or World 193 
Health Organization Grade IV astrocytoma), the most common and aggressive primary brain cancer 194 
in adults [87]. 195 
The average age at which gliomas first arise is different for the different histological lineages. For 196 
example, anaplastic astrocytomas (AAs; grade III) develops at approximately 40 years, while GBM, 197 
has a peak of incidence between 65 and 74 years of age.  198 
Malignant astrocytomas are typically invasive and highly infiltrating, and effective resection is 199 
therefore unlikely. As a consequence, patients with CNS tumors have a poor prognosis: according to 200 
the data collected by the Surveillance Epidemiology and End Results Program, the median survival 201 
time is approximately 3.5 months for patients > 65 years old at diagnosis, and about 10 months for 202 
those < 65 years [88]. The survival time is also influenced by additional factors, among which the 203 
histological features of the neoplasm, and the neurological condition and/or the general 204 
physiological status of the patient. In general terms, the effect of treatment on the overall prognosis 205 
of brain cancers is frustratingly low [87]. In a multicenter long-term study, patients treated with 206 
gliadel (bis-chloroethylnitrosourea,  or carmustine) showed a median survival of 13.8 months 207 
versus 11.6 months of placebo-treated patients [89]. A median survival of 14.6 months was instead 208 
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reported for GBM patients who underwent surgical resection, radiotherapy, and chemotherapy with 209 
temozolomide [90,91].  210 
As already mentioned, management of GBM typically consists of surgery followed by radiotherapy 211 
or chemotherapy, or both. However, because of the high infiltrating capacity of glioma cells, all 212 
therapies remain almost ineffective, residual tumor seems to be inevitable and patients eventually 213 
succumb to disease [5-7,91]. 214 
3.2 Peritumoral edema 215 
Anaplastic astrocytomas (WHO grade III), and GBM (WHO grade IV) often arise in the cerebral 216 
hemispheres. Both species can derive from a low-grade astrocytoma (WHO grade II), but can also be 217 
diagnosed de novo, without previous signs of a precursor tumor [3]. 218 
Patients with malignant astrocytomas suffer from relatively uniform symptoms and signs, including 219 
increased intracranial pressure, which depends on the growing tumor mass, and the peritumoral 220 
cerebral edema [91] (Figure 1). Brain edema is indeed typically present in human brain cancers and 221 
affect both the course and outcome of pathology [92]. The appearance and effects of edema in clinical 222 
progression of brain cancers has been known since long ago in clinical practice, and has been 223 
extensively discussed in the scientific literature. Since the nineties, two main subtypes of brain 224 
edema (cytotoxic and vasogenic) were recognized, based on their pathophysiology [1,93,94]. In 225 
cytotoxic edema, cells swell because of malfunction of Na+/K+-ATPase and sodium retention, 226 
accompanied by water excess in the ICF; the blood-brain barrier (BBB) is meanwhile intact.  On the 227 
other hand, the hallmark of vasogenic edema is breakdown of BBB, and the consequent loss of 228 
homeostasis in the neural parenchyma microenvironment. The two forms of edema, however, may 229 
share some basic mechanisms. Growing primary or secondary tumors are indeed able to release 230 
factors which promote proliferation of BCECs: thus, on one hand BCECs loose their preformed TJs, 231 
and, on the other, the nascent microvessels do not have mature TJs; this brain-tumor interface does 232 
not constitute a competent barrier, and allows leakage of plasma ultrafiltrate into the parenchyma 233 
ECF. As explained above, under normal conditions, healthy BBB restricts the movement of 234 
molecules across the vascular endothelium, and water circulation into the brain is primarily driven 235 
by hydrostatic forces (cerebral perfusion pressure) and water co-transport with solutes and ions. 236 
When TJs, which normally link together BCECs, are disrupted, extravasation of intravascular solutes 237 
(and water) is allowed, and the normal homeostasis is lost: water flows into the parenchyma along 238 
hydrostatic gradients, with no opposing osmotic forces, thus causing fluid accumulation in the ECF, 239 
in the absence of cell volume modification [94]. 240 
The most widely studied permeability and angiogenic agent secreted by tumor cells is vascular 241 
endothelial growth factor (VEGF), which induces capillary permeability, endothelial proliferation, 242 
migration, and organization of new capillaries that lack tight junctions. All the CNS tumors 243 
normally associated with edema (i.e. glioblastomas, meningiomas, and metastases) have been 244 
reported to produce high levels of VEGF [91]. 245 
The mechanisms through which water is cleared from the ECF are less clear. By using  radioactive 246 
and fluorescently labeled tracers, in animal models, it was found that, when intracranial pressure 247 
(ICP) increases, the CSF clearance of the labeled tracers decreases, suggesting activation of an 248 
alternative water clearance pathway [95]. Based on observations of this kind, several authors have 249 
hypothesized that the parenchymal route of extracellular fluid resorption, which becomes especially 250 
effective under high ICP and abnormal CSF flow dynamic, involves AQPs [94]. 251 
3.3 AQPs and Gliomas 252 
Int. J. Mol. Sci. 2016, 17, x 7 of 5 
 
As discussed above, beside water molecules which enter the brain, and move between intracellular, 253 
interstitial, vascular and ventricular compartments, together with other solutes and ions, a large part 254 
of fluid exchanges are mediated by specialized water channels called aquaporins, and are driven by 255 
osmotic and hydrostatic pressure gradients [41].  256 
Several studies have evidenced an involvement of aquaporins in multiple aspects of malignant brain 257 
tumor pathogenesis, such as promotion of tumor cell motility and invasiveness, as well as edema 258 
formation, and improvement of glycolytic tumor cell metabolism, under hypoxic conditions. [96]. 259 
Glioma cells are extremely invasive: dynamically changing their own volume, they navigate 260 
throughout the normal parenchyma, along the tortuous and narrow extracellular spaces, by 261 
following a water flux largely generated by AQPs [97,98]. On the other hand, edema represents for 262 
the patients a further critical aspect of the pathology. Given the central role of aquaporins in brain 263 
cancer growth and invasiveness, as well as in edema formation, AQPs can also represent a potential 264 
target for brain cancer therapy [94]. 265 
3.3.1 AQP1 266 
By differential gene expression analysis [99], and immunohistochemistry [100], as well as by reverse 267 
transcriptase polymerase chain reaction, complementary DNA gene array, and Western blot analysis 268 
[101], up-regulation of AQP1 was clearly demonstrated in high grade-astrocytomas. Moreover, 269 
AQP1 expression has been reported to be somehow proportional to the grade of malignancy 270 
[100-102]. Interestingly, AQP1 expression in brain cancer is associated with BCECs, which do not 271 
express this AQP in normal brain; this observation suggested that AQP1 up-regulation can be 272 
involved in vasogenic edema [69,103,104] (Figure 2). 273 
The signals that induce AQP1 expression in the endothelium of brain tumors are, however, still not 274 
completely understood, but might include production and release from cancer cells of vascular 275 
endothelial growth factor (VEGF), which can in turn increase vascular permeability, by stimulating 276 
BCEC proliferation [94]. Actually, production of VEGF is regulated, at the transcriptional level, by 277 
hypoxia, through activation of the transcription factor known as hypoxia induced factor (HIF) [105]. 278 
Moreover, since the first description done by Otto Warburg in 1931 [106], the effect of hypoxic 279 
conditions on cancer cells has been well recognized: in malignant cells, and in GBM in particular, 280 
indeed, hypoxia stimulates anaerobic glycolysis (Warburg effect), with an increase of glucose 281 
consumption and lactate production [107-109], which can persist even under normoxic conditions 282 
[96]. It has been suggested that increase of lactate induces ICF acidification, and promotes excess H+ 283 
extrusion into the ECF, probably together with water, thus providing an important function for 284 
AQP1 upregulation in cancer cells [69]. In general terms, it was found that AQP1 expression, as well 285 
as the expression of other proteins, among which lactic dehydrogenase (LDH) and the protease 286 
cathepsin B (which facilitates degradation of the extracellular matrix), correlates with glycolytic 287 
levels [69]. Taken together these modifications should allow improvement of glioma cell migration 288 
and invasion [96]. The importance of AQP1 in determining malignancy of cancer cells is also 289 
confirmed by the observation that some AQP1 polymorphisms can be used as survival prognosis 290 
factors in patients with GBM [110]. 291 
Interestingly, it has been recently reported that AQP1 (and AQP4) are upregulated even in benign 292 
subependymomas [111]. Moreover, AQP1 was also detected in meningioma cells and capillaries 293 
which invade the dura [112], also in association with the Na-K-2Cl cotransporter (NKCC1), an ions 294 
transporter which can affect fluid movements in different kinds of brain lesions [113,114].  295 
In conclusion, many studies have reported the importance of AQP1 in cerebral edema, tumor 296 
growth, angiogenesis, and neoplastic  invasiveness; one of the possible mechanisms involved seems 297 
to be induction of endothelial cell migration, depending on a water influx into the cells, with 298 
consequent expansion of their protrusions (lamellipodia) [96,97,115-117]. Based on these 299 
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observations, many Authors suggested that AQP1 blockers might function as potent anti-brain 300 
tumor edema agents. Interestingly, in the promoter of AQP1 gene, steroid responsive elements are 301 
present [118], which could be responsible for regulation of AQP expression and, in turn, for the 302 
anti-brain tumor edema action of glucocorticoids [100,119,120]. 303 
3.3.2 AQP4 304 
AQP4 is the main water channel in the brain and is expressed throughout several CNS structures, 305 
such as the ependymal cell layer lining the lateral ventricle and aqueduct, the pia mater, the choroid 306 
plexus, the hypothalamus, and the cerebellar Purkinje cells [66-68,121]. 307 
As discussed above, AQP4 is primarily an astroglial membrane protein, localized to the astrocytic 308 
endfeet which point to the cerebral microvessels [94]; in this location, AQP4 molecules contribute to 309 
form OAPs, acting as a key functional component of BBB (Figure 2). 310 
Because of this peculiar location, AQP4 has been suggested to be involved in different aspects of 311 
brain edema pathogenesis, probably with different effects depending on the nature of the disease 312 
(for example, cancer or traumatic damage), but it has not yet been fully understood the meaning of 313 
AQP4 upregulation: i) acting as a cause, due to a primary and abnormal tissue response; or ii) being 314 
only a side effect of a tissue response, aimed at eliminating fluid excess resulting from capillary 315 
leakage [75-77]. Independent of the real role of AQP4, however, there is clear evidence of a 316 
relationship between edema formation and AQP4 upregulation. For example, it has been reported 317 
that, after an ischemic stroke, AQP4 accelerates edema development [122,123], and AQP4 clearly 318 
increases after traumatic brain injury [9,124,125]. Vasogenic edema has a great effect on the 319 
morbidity and mortality associated with malignant brain tumors, and AQP4 has a major role in its 320 
pathogenesis. [96]. Bloch and Malley [2007] tested the role of AQP4 in extracellular edema, 321 
measuring intracranial pressure (ICP) and brain water content in both wild-type and AQP4-deficient 322 
mice, after a continuous infusion of artificial CSF into the brain extracellular space. They found that 323 
AQP4-deficient mice had significantly higher brain water content and two-fold greater ICP than 324 
wild-type animals, suggesting a delayed fluid clearance in these AQP4-deficient mice [94].  325 
Interestingly, a correlation has been reported between AQP4 expression and the incidence of 326 
epileptic seizures in GBM patients: in particular, it was found that, even if all GBM patients enrolled 327 
expressed similar amounts of AQP4 mRNA, patients with seizures had a higher amount of AQP4 in 328 
the cell membranes, thus suggesting a post-transcriptional regulation of AQP expression [126]. 329 
An important field of investigation concerns other molecules which could interact with AQP4 in 330 
edema formation. As in the case of AQP1 upregulation in brain cancer, one of these molecules is 331 
VEGF, which can promote tumor neovascularization, vessel permeability, and extravasation of 332 
plasma proteins into extracellular brain spaces. All these effects cause per se extensive damage of 333 
BBB integ¬rity, allowing plasmatic macromolecules to enter the interstitial space, where they 334 
produce an obvious change in osmotic pressure. It has been reported that AQP4 is positively 335 
regulated by VEGF [123,127,128]. In this context, VEGF should be the real inducer of vasogenic 336 
edema, while  upregulation and intracellular  redistribution of AQP4 should represent a protective 337 
reaction, aimed at avoiding a secondary cytotoxic brain edema, by facilitating reabsorption of excess 338 
fluid [129].  339 
In general terms, AQP4 is clearly upregulated in brain tumors, including pilocytic astrocytoma and 340 
glioblastoma [41,75-77,100,119,120,130]. A direct correlation was also found between AQP4 341 
expression and patients’ mean survival time. AQP4 expression was high in WHO I pilocytic 342 
astrocytomas (perhaps because of their peculiar vessel morphology, with a microvascular 343 
proliferation and for the presence of glomeruloid bodies), in WHO III anaplastic  astrocytomas, and 344 
in WHO IV glioblastomas (the most aggressive forms of primary brain tumors), whereas WHO II 345 
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tumors showed significantly lower AQP4 levels. Intracellular AQP4 redistribution was also 346 
significantly lower in tumor infiltration areas than in the tumor center, suggesting that the alteration 347 
of AQP4 expression pattern is specific for neoplastic regions [75-77]. 348 
A variety of reports suggest that AQP4 is involved in promoting cancer cell migration, and AQP4 349 
deletion markedly impaired, indeed, astrocytoma cell migration and invasion [66-68,100, 350 
119,120,131]. But, which can be the underlying  molecular mechanism of this effect? One possibility 351 
is that the water flux mediated by AQP4 facilitates rapid modification of cell volume and shape, thus 352 
improving movement [132]. In particular, AQP4 might allow water flow across the plasma 353 
membrane, at the level of the leading cell protrusions (lamellipodia), with an effect on their 354 
polarization, total number and size, while, at same time, these structures undergo rapid actin 355 
cytoskeleton rearrangements and changes in osmolality of the  cortical layer of cytoplasm [66-68]. 356 
Moreover, it has been suggested that AQP4-mediated water permeability at these sites, and tumor 357 
invasion, could be down-regulated by PKC activation, and AQP4 phosphorylation [98]. 358 
Interestingly, AQP4 expression was found to be higher in the peritumoral area than in the tumor 359 
core, thus suggesting a correlation between the highest AQP4 expression and the highest ability to 360 
invade the surrounding tissue [123].  361 
Probably, the most striking aspect of glioma cells respect to normal astrocytes is the completely 362 
changed organization of AQP4 complexes: as mentioned above, in the normal brain AQP4 forms 363 
OAPs specifically localized to the astrocytic endfeet; in glioma cells typical endfeet are no more 364 
recognized, and AQP4 is not only up-regulated but also redistributed along the entire cell 365 
membrane [133] (Figure 2), with a parallel loss of the normal astrocyte-BCEC contacts at the BBB 366 
[134]. As the extracellular matrix (ECM) plays an important role in the polarized localization of 367 
OAPs, AQP4 delocalization probably in turn depends on modification of ECM: it has indeed 368 
reported that, besides AQP4, dystroglycan, agrin and the matrix metalloproteinases (MMP) 2, 3 and 369 
9 also undergo altered expression in human primary glioblastomas [135]. In particular, an agrin loss 370 
has been described, probably due to its degradation by MMP 3 [41].  371 
3.3.3 AQP8 372 
The physiopathologic functions of AQP8 in brain tumors are largely unknown. Its location is, 373 
however,  different from that of AQP1 and AQP9,  suggesting a specific  role for this AQP. In a 374 
series of 75 astrocytomas of different grades, Zhu et al [2013] showed an intracellular upregulation of 375 
AQP 8 in both low- and high-grade astrocytomas, compared with normal brain tissue, with a direct 376 
correlation to the cancer grade [136]. 377 
3.3.4 AQP9 378 
AQP9 was suggested to play a role in post-ischaemic edema [137], and, given its permeability to 379 
monocarboxylates, in the clearance of lactate from the ischaemic focus [131]. Changes in AQP9 380 
expression may be the result of glial cell attempt to react to hypoxic and ischemic conditions, by 381 
facilitating clearance of lactate and glycerol, respectively. Thus, AQP9 could play a role in normal 382 
cell metabolism, under physiologic conditions, and also increase cell stress tolerance, under hypoxia 383 
and other pathological conditions  [96]. Increased AQP9 expression, both at the level of mRNA and 384 
protein,  has been also observed in astrocytic tumors of all grades [75-77,138] Jelen et al. [79] 385 
reported, however, that in glioblastoma biopsies, unlike AQP4, AQP9 is expressed only in a subset 386 
of malignant astrocytic cells and in leukocytes which infiltrate the tumor.  387 
4. Novel routes for aquaporin trafficking 388 
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Like other cancer cells, brain tumor cells produce and release into their environment extracellular 389 
vesicles (EVs), membrane structures which can derive either directly from the plasma membrane 390 
(ectosomes), through a process resembling virus budding, or from an intracellular organelle called 391 
multivescicular body (exosomes) [14,139]. EVs contain different species of mRNAs, proteins and 392 
microRNAs, which, once received by surrounding cells can alter their phenotype. EVs are also used 393 
by tumor cells to escape immune surveillance, and to discard proteins which could be otherwise able 394 
to counteract continuous proliferation and transformation of EV-producing tumor cells [14,140].  395 
Although the ability of brain cancers to produce EVs has been clearly demonstrated, it is not known 396 
whether EVs are also used for AQP trafficking and redistribution. Interestingly, however, in other 397 
tissue systems, the presence of AQPs in EVs has been reported: for example, AQP2, the 398 
vasopressin-dependent AQP expressed in kidney, has been found to be secreted into urine as 399 
exosomes [141-143], and similarly a fraction of AQP1 is released into exosomes from maturing 400 
reticulocytes [144], as well as from kidney [145]. It is therefore likely that EVs are used also by brain 401 
cancer cells to redistribute AQP channels, in order to allow faster movement of fluids which contain 402 
molecules of metabolic importance. In addition, the presence in biological fluids of EVs carrying 403 
different classes of AQPs should be perhaps of help for early diagnosis of brain tumors, and/or of 404 
their progression. 405 
5. Concluding remarks 406 
AQPs seem to play a variety of important roles in the normal brain, by coordinating water (and 407 
solutes) trafficking among the different fluid compartments of the nervous system. Exchange of 408 
water between the blood, CSF, ECF and ICF is obviously a dynamic process, but it can undergo 409 
significant modifications, both in volumes and direction, under pathological conditions, including 410 
brain cancers, as demonstrated by formation of different  kinds of edema, besides the main 411 
pathology. 412 
In the case of brain cancer, specific up-regulation of some AQPs, as well as their involvement in 413 
brain edema formation, has been consistently reported by many Authors. Moreover, recent 414 
observations have also suggested that the intensity of edema could correlate with specific AQP 415 
polymorphisms, as shown in a study on the AQP5 promoter A(-1364)C polymorphism, which is 416 
positively correlated with the intensity of brain edema in meningioma patients [146]. Based on all 417 
these findings, it has been suggested that AQPs could represent an important target in cancer/edema 418 
treatment. However, the attempts to find out molecules able to efficiently inhibit AQP channels have 419 
not been quite successful up to now, the difficulties coming from two main points: i) the high 420 
number of AQP molecules in the cell membranes, together with the spatial restrictions of these 421 
structures [147], and ii) the necessity to facilitate drug delivery across the BBB [8].  422 
Actually, it has been reported that an anti-AQP4 specific monoclonal antibody (aquaporumab) can 423 
compete and efficiently counteract binding to AQP4 of pathogenic autoantibodies produced  in 424 
neuromyelitis optica (NMO), an inflammatory disease affecting the optic nerve and spinal cord [36]. 425 
Molecules of this kind might be also useful in reducing AQP4 activity in malignant gliomas [117]. A 426 
second kind of strategy might include use of small RNAs, complementary to specific regions of 427 
AQP4 mRNA (siRNAs): it has been indeed reported that down-regulation of AQP4 by such an 428 
approach can induce cancer cell apoptosis [59,68]. 429 
In conclusion, given the importance of AQPs not only in cancer but also in many other neurologic 430 
pathologic conditions, such as traumatic injury, and stroke, it will be critical to improve the research 431 
in this field, aiming at finding out new drugs able to cross the BBB and to limit AQP up-regulation. 432 
 433 
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Legends to the Figures 965 
 966 
Figure 1 - Patient with a right frontal glioblastoma and a marked area of peritumoral edema. 967 
Images from a Brain Magnetic Resonance. The arrows point to the peritumoral edema close to the 968 
glioma:  969 
A) Sagittal  T1-weighted  970 
B) Axial T2-weighted  971 
C) Coronal T1-weighted contrast enhanced with gadolinium. 972 
 973 
Figure 2 - Alteration of expression and/or localization of AQP1 and AQP4 in brain cancer cells 974 
respect to normal glial cells. (A) in normal brain, brain capillary endothelial cells (BCECs) do not 975 
express AQP1, while AQP4 is mainly present in the astrocyte endfeet, where it forms orthogonal 976 
arrays of particles (OAPs); (B) in gliomas, BCECs express AQP1, thus probably allowing an increase 977 
of BBB permeability (large arrows), while AQP4 is delocalized: endfeet (and OAPs) are no more 978 
visible and AQP4 is found throughout the plasma membrane of glioma cells, thus probably 979 
increasing water trafficking across the cell membranes (narrow arrows on glioma cell membrane). 980 
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